SOCS3 and Optic Nerve Regeneration in Zebrafish
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
April 01, 2006 - March 31, 2008
Grant ID
G2006025
Acknowledgement
Summary
Glaucoma often leads to blindness due to optic nerve damage and retinal ganglion cell death. Optic nerve regeneration may restore vision in patients suffering from glaucoma. Unfortunately the damaged mammalian optic nerve does not readily regenerate. Interestingly, fish regenerate their optic nerve following damage and therefore provide an ideal system for studying the mechanisms underlying successful optic nerve regeneration. In a recent screen for genes that might mediate successful optic nerve regeneration in zebrafish, Dr. Goldman has identified suppressor of cytokine signaling 3 (SOCS3), which is highly induced in retinal ganglion cells that are regenerating their optic axons. SOCS3 is a multifunctional SOCS protein that not only modulates the immune response, but can also influence a number of signal transduction cascades that impact cell survival and axon outgrowth. In this grant application he proposes to test whether SOCS3 is essential for successful optic nerve regeneration. This will be accomplished by knocking down the expression of SOCS3 in adult retinal ganglion cells whose optic axons have been lesioned and assaying cell survival and optic axon regeneration in vivo.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
National Glaucoma Research
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego